Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Oxymorphone HCl

    Client Email Product

    Oxymorphone HCl

    APIs // Active Pharmaceutical Ingredients

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    GLOBAL SALES INFORMATION

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    12
    US DMFs Filed

    US DMFs Filed

    8
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    7
    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    75
    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    868.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    49

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    3

    News

    15
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    2
    SERVICES

    0

    left grey arrow
    right gray arrow
    • INJECTABLE;INJECTION - 1MG/ML
    • TABLET, EXTENDED RELEASE;ORAL - 10MG
    • TABLET, EXTENDED RELEASE;ORAL - 15MG
    • TABLET, EXTENDED RELEASE;ORAL - 20MG
    • TABLET, EXTENDED RELEASE;ORAL - 30MG
    • TABLET, EXTENDED RELEASE;ORAL - 40MG
    • TABLET, EXTENDED RELEASE;ORAL - 5MG
    • TABLET, EXTENDED RELEASE;ORAL - 7.5MG
    • TABLET, EXTENDED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    Full View ScreenFull Screen View
    U.S. subpoenas Endo for information on opioid painkillers
    U.S. subpoenas Endo for information on opioid painkillers

    https://www.reuters.com/article/us-endo-intl-subpeona/u-s-subpoenas-endo-for-information-on-opioid-painkillers-idUSKBN1F01T3

    Nate Raymond REUTERS
    11 Jan 2018
    Share Share
    Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc
    Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc

    http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-endo-international-plc---endp-300479173.html

    PR NEWSWIRE
    23 Jun 2017
    Share Share
    US FDA requests Endo Pharma remove Opana ER for risks related to abuse
    US FDA requests Endo Pharma remove Opana ER for risks related to abuse

    http://www.biospectrumasia.com/news/25/9034/us-fda-requests-endo-pharmaceuticals-to-remove-opana-er-for-risks-related-to-abuse.html

    BIOSPECTRUM
    12 Jun 2017
    Share Share
    FDA Asks Endo Pharma to Stop Selling Opana ER Amid Opioid Crisis
    FDA Asks Endo Pharma to Stop Selling Opana ER Amid Opioid Crisis

    http://www.biospace.com/News/first-time-ever-fda-asks-endo-pharma-to-stop/459477/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    Alex Keown BIOSPACE
    10 Jun 2017
    Share Share
    Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER
    Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER

    http://www.prnewswire.com/news-releases/endo-statement-on-fda-advisory-committees-vote-related-to-opana-er-300423788.html

    PR NEWSWIRE
    14 Mar 2017
    Share Share
    FDA Panel To Re-Examine Opana ER
    FDA Panel To Re-Examine Opana ER

    http://seekingalpha.com/article/4054181-fda-panel-re-examine-opana-er

    SEEKING ALPHA
    11 Mar 2017
    Share Share
    Endo Announces Agreement to Resolve FTC Investigation and Litigation
    Endo Announces Agreement to Resolve FTC Investigation and Litigation

    http://www.prnewswire.com/news-releases/endo-announces-agreement-to-resolve-federal-trade-commission-investigation-and-litigation-300394901.html

    PR NEWSWIRE
    23 Jan 2017
    Share Share
    Grunenthal says anti-crush tech Endo uses for Opana ER helps prevent abuse
    Grunenthal says anti-crush tech Endo uses for Opana ER helps prevent abuse

    http://www.in-pharmatechnologist.com/Drug-Delivery/Grunenthal-says-anti-crush-tech-Endo-uses-for-Opana-ER-helps-prevent-abuse

    Gareth MacDonald+ IN PHARMATECHNOLOGIST
    25 Aug 2016
    Share Share
    Endo withdraws abuse-deterrent labelling for Opana ER
    Endo withdraws abuse-deterrent labelling for Opana ER

    http://www.pharmatimes.com/news/endo_withdraws_abuse-deterrent_labelling_for_opana_er_1099598

    Selina McKee PHARMATIMES
    15 Aug 2016
    Share Share
    Aurolife's Generic Oxymorphone Hydrochloride approved in US for the relief of moderate to severe acute pain
    Aurolife's Generic Oxymorphone Hydrochloride approved in US for the relief of moderate to severe acute pain

    https://www.pharmacompass.com/pdf/news/aurolifes-generic-oxymorphone-hydrochloride-approved-in-us-1462019789.pdf

    FDA
    26 Apr 2016
    Share Share
    Cash is not king: FTC sues drug maker over pay-to-delay deal
    Cash is not king: FTC sues drug maker over pay-to-delay deal

    https://www.statnews.com/pharmalot/2016/03/31/patents-monopoly-antitrust/

    Ed Silverman STAT
    01 Apr 2016
    Share Share
    Depomed Acquires U.S. Rights, First-in-Class Pain Product from Grunenthal
    Depomed Acquires U.S. Rights, First-in-Class Pain Product from Grunenthal

    http://www.prnewswire.com/news-releases/depomed-acquires-us-rights-to-late-stage-first-in-class-pain-product-from-grunenthal-300180429.html

    PR NEWSWIRE
    17 Nov 2015
    Share Share
    Endo's Opana ER (Oxymorphone Hcl) Receives Supplemental Approval in US For Pain
    Endo's Opana ER (Oxymorphone Hcl) Receives Supplemental Approval in US For Pain

    https://www.pharmacompass.com/pdf/news/endo.pdf

    FDA
    24 Jun 2015
    Share Share
    Abandoned Painkiller Makes a Comeback
    Abandoned Painkiller Makes a Comeback

    http://www.medpagetoday.com/Psychiatry/Addictions/51448

     John Fauber MEDPAGE TODAY
    10 May 2015
    Share Share
    Sun's Generic Oxymorphone Hcl Approved in USA For Moderate to Severe Pain
    Sun's Generic Oxymorphone Hcl Approved in USA For Moderate to Severe Pain

    https://www.pharmacompass.com/pdf/news/suns-generic-oxymorphone-hcl-approved-in-usa-for-moderate-to-severe-pain-1443365933.pdf

    Press Release FDA
    30 Apr 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search